Chor Sang Chim

List of Publications by Year
in descending order

41 papers	799 citations	430874 18 h-index	526287 27 g-index
41 all docs	41 docs citations	41 times ranked	1492 citing authors

#	Article	IF	Citations
1	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. Therapeutic Advances in Hematology, 2022, 13, 204062072210820.	2.5	3
2	3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. Hematology, 2021, 26, 652-655.	1.5	3
3	A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. Scientific Reports, 2021, 11, 7009.	3.3	2
4	miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkinâ€™s lymphoma: novel targets with impact on ERK signaling and cell migration. Cell Communication and Signaling, 2021, 19, 62.	6.5	8
5	Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. Clinical Epigenetics, 2020, 12, 150.	4.1	11
6	Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination. Cancer Cell International, 2020, 20, 403.	4.1	11
7	Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. Journal of Pharmacy and Pharmacology, 2020, 72, 728-737.	2.4	14
8	Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. Frontiers in Oncology, 2020, 10, 611021.	2.8	3
9	Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma. Hematology, 2019, 24, 533-537.	1.5	0
10	Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. Frontiers in Oncology, 2019, 9, 449.	2.8	25
11	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clinical Epigenetics, 2019, 11, 71.	4.1	23
12	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Annals of Hematology, 2019, 98, 941-949.	1.8	9
13	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. Leukemia and Lymphoma, 2018, 59, 2305-2317.	1.3	18
14	Molecular detection of minimal residual disease in multiple myeloma. British Journal of Haematology, 2018, 181, 11-26.	2.5	39
15	Epigenetic silencing of EVL/miR-342 in multiple myeloma. Translational Research, 2018, 192, 46-53.	5.0	14
16	Epigenetic silencing of LPP/miR-28 in multiple myeloma. Journal of Clinical Pathology, 2018, 71, 253-258.	2.0	15
17	Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses. Clinical Epigenetics, 2018, 10, 158.	4.1	2
18	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. Scientific Reports, 2018, 8, 13522.	3.3	11

#	Article	IF	Citations
19	High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. Journal of Hematology and Oncology, 2016, 9, 107.	17.0	20
20	Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 82400-82410.	1.8	26
21	Infrequent DNA methylation ofmiR-9-1andmiR-9-3in multiple myeloma. Journal of Clinical Pathology, 2015, 68, 557-561.	2.0	20
22	Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Molecular Cancer, 2015, 14, 175.	19.2	40
23	DNA methylation of tumor-suppressor miRNA genes in chronic lymphocytic leukemia. Epigenomics, 2015, 7, 461-473.	2.1	24
24	<scp>LDH</scp> is an adverse prognostic factor independent of <scp>ISS</scp> in transplantâ€eligible myeloma patients receiving bortezomibâ€based induction regimens. European Journal of Haematology, 2015, 94, 330-335.	2.2	25
25	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. Epigenomics, 2015, 7, 985-1001.	2.1	29
26	Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. Oncotarget, 2015, 6, 44422-44436.	1.8	21
27	Epigenetic inactivation ofDAPK1,p14^{ARF},mir-34aand-34b/cin acute promyelocytic leukaemia. Journal of Clinical Pathology, 2014, 67, 626-631.	2.0	21
28	Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. Journal of Translational Medicine, 2014, 12, 52.	4.4	35
29	¹¹C-Acetate PET/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2014, 55, 749-752.	5.0	45
30	RANKL expression in myeloma cells is regulated by a network involving RANKL promoter methylation, DNMT1, microRNA and TNFÎ± in the microenvironment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1834-1838.	4.1	20
31	Unsustained complete response of less than 24â€‰months after autologous stem cell transplantation predicts aggressive myeloma with short survival. Hematological Oncology, 2014, 32, 205-211.	1.7	3
32	Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas. Oncotarget, 2014, 5, 9770-9782.	1.8	30
33	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFÎºB pathway. Molecular Cancer, 2013, 12, 173.	19.2	66
34	Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL. Cancer Cell International, 2013, 13, 122.	4.1	11
35	Survival of >20 years in a myeloma patient with an unusual combination of t(14;16) and hyperdiploidy: A case report. Oncology Letters, 2013, 6, 1663-1664.	1.8	2
36	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. Journal of Hematology and Oncology, 2012, 5, 28.	17.0	13

#	Article	IF	Citations
37	Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. Journal of Cellular and Molecular Medicine, 2011, 15, 2760-2767.	3.6	89
38	Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. Journal of Translational Medicine, 2011, 9, 197.	4.4	38
39	Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients. Journal of Translational Medicine, 2010, 8, 124.	4.4	7
40	PAD Induction Therapy Followed by Autologous Peripheral Blood Stem Cell Transplant (APBSCT) as Upfront Treatment for Myeloma (MM) in Chinese Patients.. Blood, 2009, 114, 4367-4367.	1.4	0
41	GI manifestations of mantle cell lymphoma. Gastrointestinal Endoscopy, 2003, 58, 931-933.	1.0	3